期刊
CURRENT CANCER DRUG TARGETS
卷 16, 期 9, 页码 755-764出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009615666151030102250
关键词
Cancer immunotherapy; combination therapy; indoleamine 2,3-dioxygenase (IDO); IDO inhibitors; immune tolerance
类别
资金
- American Cancer Society [IRG - 08-060-04]
Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据